A new Special Collection in Ther Adv Med Oncol will explore emerging treatment strategies in HR+HER2‑ advanced #BreastCancer, a field marked by rapid therapeutic expansion and ongoing unmet need.
Submission deadline: 14 Dec 2026
buff.ly/Da8ENXI
#HRpositive #HER2negative #MedicalOncology

What does it take to be successful? This piece from @TLNT_com provides some insight.
#NEWROI #HRPositive #HRonPurpose

buff.ly/2yAgUjb

This quote was an easy way to explain the premise of the book, The NEW ROI: Return On Individuals. I'm honored that it has now made this List of Motivational Quotes - Thank you @JoannaLangier#NEWROI #HR #SHRM #HRonPurpose #HRPositive #leadership

buff.ly/2H0c5A2

HR+/HER2‑ Breast Cancer Market Trends Reflect Rapid Adoption of Personalized Treatments

Source: roleplay.iland.top/blogs/11602/...

#HRPositive #HER2Negative #BreastCancerMarket #OncologyMarket #CancerTherapeutics

In a phase 3 trial, #culmerciclib plus #fulvestrant improved PFS and response rates versus fulvestrant alone in pretreated #HRPositive, #HER2Negative advanced #BreastCancer, supporting dual CDK2/4/6 targeting to overcome resistance.

#OpenAccess in #STTT: doi.org/10.1038/s413...

🔷 Findings from BRIGHT-2 provide important insights into combination therapy approaches for HR+ advanced breast cancer following endocrine progression.

🔗 Read more: bit.ly/ONCOnews-23-...

#ONCOnews #OncoAlert #OncEd #BreastCancer #AdvancedBreastCancer #HRPositive #Oncology #CancerResearch